News

Optimer Pharmaceuticals Announces Presentations Of Additional Fidaxomicin Phase 3 Data At Upcoming ICAAC Annual Meeting

Results from studies related to Optimer Pharmaceuticals, Inc.'s (Nasdaq: OPTR) lead developmental p...

Halozyme Begins Phase 2 Clinical Trials With Insulin Analogs Lispro And Aspart With RHuPH20 In Type 1 And Type 2 Diabetes

Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced the initiation of two Phase 2 Ultrafast Insuli...

Inhibitex Successfully Completes Phase 1a Trial Of INX-189

Inhibitex, Inc. (Nasdaq: INHX), announced that it has successfully completed a Phase1a, first-in-man...

Transdel Pharmaceuticals Presents Phase 3 Study Data On Ketotransdel® At World Pain Congress In Montreal, Canada

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focus...

Soligenix Announces Publication Of Article Identifying Domains Within The Ricin Toxin A Subunit As Targets Of Protective Antibodies

Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutic...

For our Researchers

From improving access to research & development information, to increasing access to specialised research advice, a key aim of TAHSC is to enhance the research support for both institutions therefore making it easier for all health professionals to participate in research within Tayside.